Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies

Conclusion: 111In-DOTA-BC8 had a long retention time in liver, spleen, kidneys, and red marrow, and the highest absorbed doses were in spleen and liver. Few differences were observed by malignancy type. The exception was greater splenic uptake in the leukemia/MDS group than in the lymphoma or multiple myeloma group.

Source: Journal of Nuclear Medicine - August 31, 2020 Category: Nuclear Medicine Authors: Matesan, M., Fisher, D. R., Wong, R., Gopal, A. K., Green, D. J., Sandmaier, B. M., Bensinger, W., Pagel, J. M., Orozco, J., Press, O. W., Cassaday, R. D., Hutchinson, E., Wanner, M., Pal, S., Thostenson, C., Rajendran, J. G. Tags: Clinical Source Type: research